ArticleCancer medicine2026

Pertuzumab Vs. Pyrotinib in Combination With Trastuzumab and Taxanes for First-Line Treatment of HER2+ MBC: A Multicenter Real-World Study.

Meiqiong Kuang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.